10074-G5: Small-Molecule c-Myc Inhibitor for Advanced Cancer Research

Principle and Setup: Targeting the c-Myc/Max Axis in Cancer

The c-Myc transcription factor is a central node in proliferation, metabolism, and survival pathways that drive tumorigenesis in a wide array of cancers. Overexpression and dysregulation of c-Myc, frequently observed in aggressive malignancies such as esophageal adenocarcinoma, B-cell lymphoma, and breast cancer, are correlated with poor prognosis and therapy resistance. 10074-G5, available from APExBIO as SKU C5722, is a potent small-molecule c-Myc/Max dimerization inhibitor designed to directly disrupt the protein-protein interaction required for c-Myc’s transcriptional activity.

Functionally, 10074-G5 impedes the assembly of the c-Myc/Max heterodimer, halting downstream c-Myc signaling cascades implicated in cell cycle progression, metabolic reprogramming, differentiation blockade, and apoptotic evasion. The compound’s mechanism is especially relevant in research settings examining the molecular underpinnings of oncogenic transcription factor inhibition and the dynamic c-Myc signaling pathway.

• Chemical Properties: C₁₈H₁₂N₄O₃, MW 332.3, crystalline solid
• Solubility: ≥37.9 mg/mL in DMSO, ≥3.53 mg/mL in ethanol (with ultrasonic assistance), insoluble in water
• Purity: ~98% (lot-dependent)
• Storage: -20°C; solutions not recommended for long-term storage
• In vitro activity: IC₅₀ = 15.6 ± 1.5 μM (Daudi), 13.5 ± 2.1 μM (HL-60)
• In vivo efficacy: 20 mg/kg (IV, 10 days) significantly suppresses Daudi xenograft tumor growth without affecting body weight

This targeted, quantifiable disruption of c-Myc/Max interaction makes 10074-G5 an indispensable tool for dissecting the oncogenic transcription factor’s role and advancing anticancer drug development pipelines.

Step-by-Step Workflow: Optimizing Experimental Design with 10074-G5

1. Compound Preparation & Handling

• Dissolve crystalline 10074-G5 in DMSO at ≥37.9 mg/mL for stock solutions. For ethanol, ultrasonic bath treatment is recommended for complete solubilization (≥3.53 mg/mL).
• Aliquot and store at -20°C. Avoid repeated freeze-thaw cycles and prepare fresh working dilutions immediately prior to use to preserve compound integrity.
• Note: Solutions are not recommended for long-term storage due to potential degradation, which can impact reproducibility.

2. Cell-Based Assays

• Cell Viability & Proliferation: Treat cancer cell lines (e.g., Daudi, HL-60, EAC models) with a concentration range (1-30 μM) of 10074-G5. Use MTT, CellTiter-Glo, or trypan blue exclusion assays to quantify cytostatic/cytotoxic effects. IC₅₀ values provide a benchmark for potency assessment.
• Apoptosis Assays: Employ Annexin V/PI staining and caspase-3/7 activation assays post-treatment. Studies consistently observe dose-dependent induction of apoptosis, aligning with c-Myc pathway inhibition.
• Cell Cycle Arrest: Use flow cytometry (propidium iodide or BrdU incorporation) to track 10074-G5-induced G1 arrest. Quantify sub-G1 population as a marker of apoptotic DNA fragmentation.
• Western Blot / Immunofluorescence: Probe for c-Myc, Max, cleaved PARP, Cyclin D1, and additional pathway markers. 10074-G5 at 10 μM effectively reduces total c-Myc protein levels and downstream effectors.

3. In Vivo Xenograft Studies

• For tumor regression studies, inject 10074-G5 intravenously at 20 mg/kg daily for 10 days in immunodeficient mice bearing Daudi or EAC xenografts. Monitor tumor volume and body weight to gauge efficacy and systemic toxicity.
• Harvest tumors for histological and molecular endpoint analysis (H&E, IHC for Ki67, c-Myc, cleaved Caspase-3).

4. Data Analysis & Controls

• Include vehicle (DMSO) and positive control (e.g., established chemotherapeutic agent) arms for comparative assessment.
• Apply statistical tools (ANOVA, t-tests) to determine significance of observed effects.

For comprehensive, scenario-based guidance, see the cell-based workflow article, which complements this overview by diving into day-to-day troubleshooting and data fidelity strategies when using 10074-G5.

Advanced Applications & Comparative Advantages

10074-G5’s ability to disrupt the c-Myc/Max dimer interface provides unique leverage in both basic and translational oncology research. Recent advancements, such as the identification of the MYC/TERT/NFκB axis in esophageal adenocarcinoma aggressiveness (García-Castillo et al., 2025), underscore the necessity of precise c-Myc pathway modulation tools.

• Molecular Dissection of Oncogenic Networks: By selectively inhibiting c-Myc/Max dimerization, 10074-G5 allows researchers to parse the contribution of c-Myc to epithelial-to-mesenchymal transition (EMT), telomerase (TERT) upregulation, and NFκB signaling—critical events in tumor progression and metastasis, as highlighted in the referenced Molecular Oncology study.
• High Purity and Reliable Performance: With a typical purity of ~98% and robust IC₅₀ values in both hematologic and solid tumor models, 10074-G5 ensures reproducible, high-fidelity experimental outcomes, a fact echoed across multiple independent reviews (see here).
• Translational Relevance: In vivo studies demonstrate that 10074-G5 can suppress c-Myc-driven tumor growth without apparent systemic toxicity, providing a bridge from bench to preclinical validation.

These features position 10074-G5 as a transformative reagent for advanced cancer models, including those leveraging patient-derived cells, organoids, or in vivo xenograft systems. For a broader exploration of mechanism and comparative utility, the article "Targeting c-Myc/Max Dimerization for Advanced Cancer Models" extends on these points, offering insight into how 10074-G5 complements peptide-based or genetic c-Myc inhibition approaches.

Troubleshooting & Technical Optimization

Common Challenges and Solutions

• Solubility Issues: If undissolved particulates are observed, vortex and sonicate stock solutions; ensure DMSO or ethanol is at room temperature before dissolving. Avoid water as a solvent.
• Cytotoxicity Variability: Confirm cell line authentication and passage number. Adjust treatment duration (24-72 hours) and ensure even compound distribution by gentle pipetting or orbital shaking.
• Off-Target Effects: Include non-cancerous cell controls to distinguish c-Myc-specific effects. Use isogenic c-Myc knockout lines where feasible.
• Assay Interference: DMSO concentrations above 0.1-0.2% (v/v) may affect cell health—keep vehicle control matched and minimize solvent volume.
• Compound Stability: Prepare working dilutions fresh each time. Avoid exposure to moisture and light, which can degrade 10074-G5 and compromise activity.

Experimental Enhancements

• Combining with Pathway Modulators: To dissect c-Myc axis crosstalk (e.g., with TERT or NFκB), use 10074-G5 in combination with specific inhibitors or siRNAs. This is particularly relevant for studies inspired by García-Castillo et al., where multi-axis targeting reversed EMT and reduced tumor cell motility.
• Workflow Integration: Incorporate 10074-G5 into high-content imaging or multiplex cytometry platforms for deeper phenotypic profiling.
• Documentation: Keep detailed logs of lot numbers, storage conditions, and experimental parameters to enable cross-study validation and reproducibility.

For more scenario-driven advice, "A Benchmark Small-Molecule c-Myc Inhibitor for Tumor Regression Studies" extends this guidance, highlighting real-world troubleshooting and workflow streamlining with APExBIO’s 10074-G5.

Future Outlook: c-Myc Inhibition in Precision Oncology

The integration of small-molecule c-Myc/Max dimerization inhibitors like 10074-G5 into both discovery and translational research workflows is reshaping cancer biology. As highlighted in the recent Molecular Oncology study, targeting the MYC/TERT/NFκB axis has direct implications for reversing aggressive cancer phenotypes and may inform future therapeutic strategies in hard-to-treat malignancies such as esophageal adenocarcinoma.

Looking ahead, advances in structure-guided drug design and combination therapy regimens are poised to further enhance the specificity and efficacy of c-Myc inhibitors. 10074-G5, with its established reproducibility, quantifiable performance, and trusted supply chain from APExBIO, remains a gold standard for researchers seeking to unravel the complexities of oncogenic transcription factor networks and accelerate anticancer drug development.

Whether employed in apoptosis assay optimization, cell cycle arrest studies, or preclinical tumor regression models, 10074-G5 continues to set the benchmark for reliability and scientific impact in cancer research. For detailed product specifications and ordering, visit the 10074-G5 product page.